Access the full text.
Sign up today, get DeepDyve free for 14 days.
著者 DJZareba, WHall WJBrown, MWLin ACAndrews, MLBurke MMoss (2004)
Time Dependence of Mortality Risk and Defibrillator Benefit After Myocardial InfarctionCirculation: Journal of the American Heart Association, 109
AE Epstein, JP DiMarco, KA Ellenbogen (2008)
ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) [published correction appears in Circulation. 2009;120(5):e34-e35]., 117
S. Hohnloser, K. Kuck, P. Dorian, R. Roberts, J. Hampton, R. Hatala, E. Fain, M. Gent, S. Connolly (2004)
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.The New England journal of medicine, 351 24
Priorities for Personalized Medicine.
G. Steinbeck, D. Andresen, K. Seidl, J. Brachmann, E. Hoffmann, D. Wojciechowski, Z. Kornacewicz‐Jach, B. Sredniawa, G. Lupkovics, F. Hofgärtner, A. Lubiński, M. Rosenqvist, A. Habets, K. Wegscheider, J. Senges (2009)
Defibrillator implantation early after myocardial infarction.The New England journal of medicine, 361 15
T. VanderWeele, M. Knol (2011)
Interpretation of Subgroup Analyses in Randomized Trials: Heterogeneity Versus Secondary InterventionsAnnals of Internal Medicine, 154
I. Goldenberg, Anant Vyas, W. Hall, A. Moss, Hongyue Wang, Hua He, W. Zareba, S. McNitt, M. Andrews, Madit-Ii Investigators (2008)
Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.Journal of the American College of Cardiology, 51 3
J. Oss, W. Areba, W. Ackson, H. Lein, D. Ilber, D. Annom, J. Ames, P. Aubert, S. Iggins, M. Rown, M. Ndrews (2002)
PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTIONThe New England Journal of Medicine, 346
J. Goldberger, A. Buxton, M. Cain, O. Costantini, D. Exner, B. Knight, D. Lloyd‐Jones, A. Kadish, Byron Lee, A. Moss, R. Myerburg, J. Olgin, R. Passman, D. Rosenbaum, W. Stevenson, W. Zareba, D. Zipes (2011)
Risk Stratification for Arrhythmic Sudden Cardiac Death: Identifying the RoadblocksCirculation, 123
J. Goldberger, R. Passman (2009)
Implantable cardioverter-defibrillator therapy after acute myocardial infarction: the results are not shocking.Journal of the American College of Cardiology, 54 22
A. Epstein, J. Dimarco, K. Ellenbogen, N. Estes, R. Freedman, L. Gettes, A. Gillinov, G. Gregoratos, S. Hammill, D. Hayes, M. Hlatky, L. Newby, R. Page, M. Schoenfeld, M. Silka, L. Stevenson, M. Sweeney, Sidney Smith, A. Jacobs, C. Adams, Jeffrey Anderson, C. Buller, M. Creager, S. Ettinger, D. Faxon, J. Halperin, L. Hiratzka, S. Hunt, H. Krumholz, F. Kushner, B. Lytle, Rick Nishimura, J. Ornato, Barbara Riegel, L. Tarkington, C. Yancy (2008)
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac PacemakerCirculation, 117 21
VIEWPOINT ONLINE FIRST Personalized Medicine vs Guideline-Based Medicine guidelines are applied in clinical practice differ in certain criti- Jeffrey J. Goldberger, MD, MBA cal characteristics from those of the trial population on which Alfred E. Buxton, MD the guideline recommendation is based. That is, the general- izabilityoftrialresultstoclinicalpracticemaybecompromised WO PHILOSOPHICAL APPROACHES TO THE IMPLEMEN- by a number of factors involved in execution of the trial, such tation of optimal health care are emerging—the use as where patients were recruited (eg, inpatient vs outpatient of evidence-based guidelines and the application of venue, tertiary referral centers vs primary care centers). Tpersonalized (or “precision”) medicine. Even though The President’s Council of Advisors on Science and Tech- both approaches have important merits, they both also can nology noted that personalized medicine “refers to the tai- present conflicting priorities that must be reconciled be- loring of medical treatment to the individual characteris- fore they can be best leveraged. tics of each patient. It does not literally mean the creation Evidence-based guidelines are generated based on the body of drugs or medical devices that are unique to a patient, but of clinical data available for a particular question. The highest rather the ability to classify individuals
JAMA – American Medical Association
Published: Jun 26, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.